Biocon Launches ₹4,150-Crore QIP at ₹387.74 Floor Price

• Biocon Limited's board approved a Qualified Institutional Placement (QIP) of ₹4,150 crore.
• The floor price for the QIP is set at ₹387.74 per equity share, with the issue opening on January 12, 2026.
• The company may offer a discount of up to 5% on the floor price, making the indicative issue price ₹368.35.
• Biocon's subsidiary plans to launch three new oncology biosimilars, reinforcing its commitment to affordable cancer care.
• Ajanta Pharma signed an in-licensing agreement with Biocon for marketing semaglutide in 26 countries.

Why It Matters: Biocon initiates a major QIP to raise ₹4,150 crore, alongside strategic moves in biosimilars and diabetes care.